A US Senate bill to specifically allow the use of CBD and other hemp derivatives in dietary supplements and foods has been introduced with bipartisan sponsorship. The bill also enjoys broad support within the industry.
The hemp/CBD industry may have gotten the cart before the horse in terms of extraction capacity and raw material supply, said an investment analyst familiar with the sector.
By Hank Schultz, Elaine Watson and Elizabeth Crawford
A report on CBD delivered by FDA Commissioner Dr Stephen Hahn, MD, was seen by food and dietary supplement industry stakeholders as offering little hope of a timely regulatory solution for the ingredient.
FDA Commissioner Dr Stephen Hahn, MD, in a speech on Wednesday, said that despite its continued concern about insufficient safety data, the FDA has no plans to try to shut down the CBD markets. Hahn said that would amount to a “fool’s game.”
Dietary supplement industry stakeholders are divided over whether proposed legislation to alter the regulatory definitions of dietary ingredients to specifically include CBD is the best way to break the logjam on the substance.
